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Osteoarthritis (OA) is an age-related condition and the leading cause of pain, disability and shortening of
adult working life in the UK. The incidence of OA increases with age, with 25% of the over 50s population
having OA of the knee. Despite promising preclinical data covering various molecule classes, there is
regrettably at present no approved disease-modifying OA drugs (DMOADs). With the advent of next
generation sequencing technologies, other therapeutic areas, in particular oncology, have experienced a
paradigm shift towards deﬁning disease by its molecular composition. This paradigm shift has enabled
high resolution patient stratiﬁcation and supported the emergence of personalised or precision medi-
cines. In this review we evaluate the potential for the development of OA therapeutics to undergo a
similar paradigm shift given that OA is increasingly being recognised as a heterogeneous disease
affecting multiple joint tissues. We highlight the evidence for the role of these tissues in OA pathology as
different “hallmarks” of OA biology and review the opportunities to identify and develop targeted
disease-modifying pharmacological therapeutics. Finally, we consider whether it is feasible to expect the
emergence of personalised disease-modifying medicines for patients with OA and how this might be
achieved.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.The unmet clinical need in OA for a personalised disease-
modifying therapeutic
Osteoarthritis (OA) is an age-related condition and the leading
cause of pain, disability and shortening of adult working life in the
UK. The incidence of OA increases with age, with 25% of the over
50s population having OA of the knee1. Despite this prevalence, and
in contrast to rheumatoid arthritis2, there are currently no effective
Disease-Modifying OA Drugs (DMOADs) which havemet regulatory
approval.
Clinical management of OA typically entails a limited combi-
nation of pharmacological and non-pharmacological treatment
options to reduce pain and increase tolerance for functional activ-
ity2. Unfortunately, Non-Steroidal Anti-Inﬂammatory Drugs
(NSAIDs) either do not modify the disease course or have beento: S.W. Jones, MRC-ARUK
of Immunity and Infection,
, UK. Tel: 44-121-3713224;
onge), s.w.jones@bham.ac.uk
ternational. Published by Elsevier Lassociated with serious renal and cardiovascular effects and
gastrointestinal bleeding in the clinic3. Patients with knee OA can
be offered intra-articular corticosteroid injections which can be
effective in some patients in providing pain relief, but the beneﬁt is
short-lived and frequent injections can damage the articular
cartilage. Recent studies have reported structural beneﬁts with
dietary Glucosamine supplementation in patients with knee OA4.
Some of these supplements therefore hold great promise, and may
in the future be part of a holistic treatment approach. However,
currently they are not recommended by OARSI and ACR5. Ulti-
mately therefore, many patients with knee or hip OA will undergo
surgery to replace the diseased joint.
In stark contrast, our understanding and subsequent treatment
of cancer has changed dramatically over the last 10e15 years. The
emergence of molecular biology combined with next generation
sequencing approaches has enabled a paradigm shift from labelling
cancer by anatomical location and tissue type, to being deﬁned by
its molecular genetics phenotype. Importantly, this paradigm shift
has facilitated the emergence of personalised therapeutics. The
importance of developing personalised therapeutics was high-
lighted during the clinical studies of Iressa (Geﬁtinib), developed by
AstraZeneca for patients with non-small cell lung cancer (NSCLC) totd. All rights reserved.
D.P. Tonge et al. / Osteoarthritis and Cartilage 22 (2014) 609e621610target the epidermal growth factor receptor (EGFR). Initial clinical
trials with Geﬁtinib were conducted with a large mixed patient
cohort and did not show overall efﬁcacy. However, retrospective
analysis revealed that the drug was efﬁcacious in approximately
10% of patients whose lung cancer exhibited activating EGFR mu-
tations7. This illustrates the importance of improved proﬁling of
patient populations so that patients are stratiﬁed to ﬁnd the right
drug for the right patient. This personalisedmedicine approach also
facilitates smaller, more targeted trial designs with a greater chance
of meaningful outcomes.
Furthermore, because of our understanding of cancer biology as
a multi-faceted disease, therapeutics have been developed which
are designed to target different hallmarks of cancer biology, from
tumour cell growth and apoptosis, tumour metabolism to anti-
angiogenic drugs which target the tumour vasculature, for
example the VEGF antibody Avastin (bevacizumab). These different
therapeutic strategies offer a multitude of potential therapeutic
targets and also are now opening the door to the study of combi-
nation therapeutics which will likely lead to a further step-change
in drug efﬁcacy8.
In this review we evaluate the potential for the development of
OA pharmacological disease-modifying therapeutics to undergo a
similar paradigm shift given that OA is increasingly being recog-
nised as a heterogeneous disease and one that involves the whole
joint, encompassing multiple tissue types including cartilage, bone,
adipose and skeletal muscle. We brieﬂy highlight the evidence for
the role of these tissues in OA pathology and review the opportu-
nities within each of these tissues to identify and develop targeted
disease-modifying therapeutics (Fig. 1 & Table I). We also consider
whether it is feasible to expect the emergence of personalisedFig. 1. Representation of the multiple biological effect areas within the OA joint and key
recognised as a disease of the whole joint (encompassing cartilage, subchondral bone, syno
drug targets, new drug combinations and re-proﬁling old drugs from other therapeutic aredisease-modifying medicines for patients with OA and how this
might be achieved.
Biological effect areas in OA for identifying potential
therapeutic targets
Targeting cartilage matrix degradation
OA is characterised by the degradation of cartilage matrix
components, including cartilage speciﬁc type II collagen and the
proteoglycan aggrecan9, ultimately resulting in the loss of cartilage
structure and function. Targeting cartilage matrix degeneration is a
well explored area for drug target discovery, and therefore the
majority of what could be termed “low-hanging fruit” have already
been picked. However, given that there are thought to be several
key anabolic and catabolic pathways enzymes that are dysregulated
in OA cartilage10, there remains the opportunity to identify and
validate new drug targets. In addition, there are also the untapped
opportunities to explore and identify novel combinations from
combining existing known targets. For example by combining
therapeutics that are anti-catabolic with those that activate
anabolic signalling pathways. As in cancer drug discovery, these are
areas which should be investigated to identify a novel efﬁcacious
combination from combining known targets.
Matrix metalloproteinases (MMPs), a diverse family of zinc-
dependent proteolytic enzymes involved in the maintenance of
the extracellular matrix11, were initially seen as attractive drug
targets for the treatment of OA12 and indeed other therapeutic
areas including cardiovascular disease and cancer13e15. However,
despite several candidates showing good efﬁcacy in preclinicalpathways to exploit for the development of pharmacological DMOADs. OA is widely
vium, skeletal muscle and adipose tissue), offering new opportunities to identify new
as.
Table I
Pharmacological targets and approaches for OA disease modiﬁcation. For each clinical trial cited, the quality of evidence is included in superscript; 1 refers to a randomised controlled trial
Biological effect
area
Therapeutic
target
Mode of action Preclinical strength of hypothesis Clinical data (quality of evidence in
superscript)
In vitro In vivo
Cartilage
Matrix
MMPs (pan)
MMP-13
Inhibition of MMP proteases
to prevent Type II Collagen
degradation.
Efﬁcacy demonstrated in bovine and
human cartilage explants using small
molecule pan-MMP inhibitors and a
selective MMP-13 inhibitor12.
Efﬁcacy demonstrated in rodent and canine models of
OA12,19.
Terminated in Phase I/II due to
musculoskeletal toxicity.
NCT000417561
ADAMTS-4
ADAMTS-5
Inhibition of aggrenases to
prevent proteoglycan
degradation.
Inhibition of ADAMTS-4 and 5
attenuated the degradation of aggrecan
in cytokine stimulated normal cartilage
explants and un-stimulated OA
explants130.
ADAMTS-4/ADAMTS-5 inhibitors show
efﬁcacy in reducing CTXII release from
human cartilage explants stimulation
with interleukin-1, onocstatin-M and
plasminogen131.
ADAMTS-5 knockout mouse is protected from aggrecan loss
following surgically induced joint instability20.
ADAMTS-4/ADAMTS-5 inhibitor reduces the production of
aggrecanase speciﬁc neo-epitope in the Dunkin Hartley
guinea pig131.
AGG-523 (ADAMTS4/5 inhibitor) e
poor pharmacokinetics identiﬁed in
Phase I study.
NCT004276871
NCT004542981
Fibroblast
Growth
Factors
FGF-18
Induction of type II Col
and proteoglycan synthesis.
rFGF and rFGF18 induce type II collagen
and proteoglycan synthesis in
cartilage23.
rFGF18 promotes cartilage repair in the rodent meniscal
tear model of OA24.
Candidate drugs currently in Phase I/II
studies.
NCT010668711
NCT016893371
NCT019191641
BMP-7/OP-1 Induction of type II Col and
proteoglycan synthesis.
rOP-1 induces synthesis of collagen and
proteoglycan in cartilage26.
rOP-1 promotes cartilage repair and reduces pain27,28. Candidate drugs currently in Phase I
studies.
NCT004561571 NCT011336131
NCT011110451
Bone Cathepsin K Reduction in osteoclast
resorption efﬁciency.
Inhibition of cathepsin K shown to
reduce osteoclast resorption efﬁciency
whilst maintaining other cellular
functions in murine and human
osteoclasts49.
CatK deletion increases bone mass48. Pharmacological
inhibition of CatK shown to protect subchondral bone
integrity, reduce the incidence osteophytosis, reduce
cartilage degeneration and improve joint pain46,52,53.
Bisphosphonates Induction of osteoclast
apoptosis.
Induction of marked osteoclast
apoptosis conﬁrmed in murine
osteoclast cell culture132.
Tiludronate demonstrated a positive effect on gait disability
and joint symptoms in a canine model of OA133.
Several studies have shown that
bisphosphonate administration has
positive effects on joint pain in various
osteoarthritic sites e reviewed by40.
Lack of DMOAD efﬁcacy reported in
Phase II study Laslett et al., 2013
Calcitonin Inhibits osteoclast bone
resorption activity.
Calcitonin inhibits osteoclast bone
resorption in vitro134.
Reduction of cartilage loss and subchondral bone damage
following calcitonin administration in a murine model of
traumatic OA42.
Terminated in Phase III due to reported
toxicity.
NCT003763111 NCT007048471
Strontium Inhibits osteoclast bone
resorption activity.
Strontium inhibits bone resorption43
and stimulates bone formation44.
Reduces progression in a canine model of OA45. Evidence of slowed JSN in knee OA.
ISRCTN413233721
Inﬂammation COX-2 Inhibition of arachidonic
acid pathway.
COX-2 inhibition reversed cartilage
matrix degradation in human articular
cartilage cultures stimulated with
peripheral blood mononuclear cells, IL-
1b and TNF-a135.
COX-2 inhibition reduced histological changes and
suppressed chondrocyte apoptosis in a rodent instability
model of OA136.
Terminated due to cardiovascular
toxicity.
TNF-a mAb to block TNF-a
inﬂammatory signalling.
Inﬂiximab and Etanercept suppress
TNF-a induced NO production in human
cartilage explants from OA patients137.
Anti-TNF-a administration signiﬁcantly reduced developing
joint pathology in a murine model of collagen-induced
arthritis (CIA) however had little effect on established
CIA138.
Reduction in Mankin score noted in meniscectomised
rabbits following administration of Inﬂiximab139.
Lack of DMOAD efﬁcacy reported in
Phase II study of patients with hand OA.
NCT005976231
IL-1b Block IL-1b inﬂammatory
signalling.
Reduction in inﬂammatory mediators (including TNF-a and
MMP-13) following blockade of IL-1b by gene knockdown
in the Dunkin Hartley strain guinea pig140.
Pralnacasan reduced joint damage in two murine models of
Terminated in Phase II due to reported
liver toxicity in a 9-month animal study.
(Pralnacasan).
(continued on next page)
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D.P. Tonge et al. / Osteoarthritis and Cartilage 22 (2014) 609e621612disease models, the development of MMP inhibitors has been
limited by their tendency to elicit various undesirable musculo-
skeletal pathologies in both preclinical models and in the clinic, at
efﬁcacious blood concentrations9,16e18.
Selectivity proﬁling initially suggested that the inhibition of
interstitial collagenase (MMP-1) and matrilysin (MMP-7) were
responsible for the musculoskeletal symptoms associated with
broad-spectrum MMP inhibitors16. Recent in vitro studies have
concentrated on the development of inhibitors which speciﬁcally
target MMP-13, a key MMP expressed in human OA cartilage9,
whilst maintaining selectivity against other MMPs. Furthermore,
inhibitors such as ALS 1-063512 and PF-15219 have demonstrated
chondroprotective effects in rodent and canine preclinical studies
with no reported evidence of musculoskeletal pathology. However,
a human clinical trial involving knee OA patients receiving the
MMP inhibitor PG-116800 (PG-530742) which has low afﬁnity for
both MMP-1 and MMP-716 (NCT00041756) was unfortunately
terminated due to musculoskeletal toxicity. Although these highly
speciﬁc MMP inhibitors may offer signiﬁcant therapeutic potential,
no such molecules have yet been approved for use in the clinic and
concerns remain that the muscle toxicity may be due to the
molecule class. As such no further clinical trials are currently un-
derway investigating MMP inhibitors in OA.
With concerns regarding MMP inhibitor safety proﬁles, an
alternative approach is to develop inhibitors which target the
aggrecanases, members of the ADAMTS family which are the major
enzymes responsible for aggrecan cleavage during early cartilage
remodelling. In vitro studies using functional antibodies or siRNA
have implicated aggrecanase 1 (ADAMTS-4) and aggrecanase 2
(ADAMTS-5) as the key aggrecanases in mediating aggrecan
cleavage in pig and bovine articular cartilage.
Currently, the relative contribution of ADAMTS-4 and ADAMTS-
5 proteinases to aggrecan loss and early cartilage erosion in OA has
not been fully established. Studies using an ADAMTS-5 knockout
showed that mice deﬁcient in ADAMTS-5 (but not ADAMTS-4) were
protected from early aggrecan loss and cartilage erosion in both
inﬂammatory and surgical preclinical models of OA20,21 however it
is not yet known whether these ﬁndings will translate to human
OA. Developing pharmacological aggrecanase inhibitors into the
clinic has proven difﬁcult due to poor pharmacokinetic (PK) prop-
erties with this class of inhibitor resulting in poor systemic expo-
sure unless potency is compromised. As such, only one aggrecanase
inhibitor has been trialled in the clinic, AGG-523, an ADAMTS4/5
dual inhibitor which was investigated in two Phase I studies in
patients with mild to moderate (clinical trial NCT00427687) and
severe (clinical trial NCT00454298) knee OA. Exploring the poten-
tial synergistic efﬁcacy of combining an aggrecanase inhibitor with
a selective MMP inhibitor, or indeed a pro-anabolic drug may be
one way forward in achieving an efﬁcacious therapeutic drug with
suitable PK properties.
Targeting anabolic pathways to promote cartilage repair is an
alternative strategy for preventing cartilage degeneration. Mem-
bers of the ﬁbroblast growth factors (FGF) family of growth factors,
FGF-2 and FGF-18, have been implicated in the regulation of
articular cartilage homeostasis and repair22. In vitro and in vivo
studies have demonstrated the cartilage anabolic effects of re-
combinant FGF in inducing type II collagen formation and pro-
moting proteoglycan synthesis23, whilst FGF-18 administration has
been shown to induce cartilage repair in rodent preclinical models
of OA24. Recombinant FGF-18 is currently the focus of several
clinical trials including studies investigating its efﬁcacy in stimu-
lating cartilage repair following injury and micro-fracture surgery,
and its effect on slowing disease progression in a cohort of knee OA
patients (clinical trial identity numbers NCT01066871,
NCT01689337, NCT01919164 respectively). Currently, it remains to
D.P. Tonge et al. / Osteoarthritis and Cartilage 22 (2014) 609e621 613be seenwhether the anabolic effects on cartilage seen in preclinical
models are replicated in the clinic.
Bone morphogenetic protein-7 (BMP-7, osteogenic Protein-1) is
another growth factor that has been investigated as a potential
therapeutic target to promote OA articular cartilage repair. BMP-7
levels are lower in OA diseased cartilage compared to normal
cartilage25 and in vitro and ex-vivo studies have demonstrated the
pro-anabolic effect of BMP-7 on cartilage of stimulating the syn-
thesis of matrix components and increasing collagen and proteo-
glycan synthesis26. Preclinical data suggests that the administration
of recombinant human BMP-7 has reparative effects on cartilage
and improves symptoms of joint pain27,28. Three clinical trials have
investigated the administration of BMP-7 in patients with knee OA
to date. A small phase 1 safety and tolerability study of BMP-7 in
w30 patients with knee OA reported aw20% improvement in pain
in the absence of any dose limiting toxicity (NCT01111045)27. Re-
sults are currently awaited from two further dose ﬁnding and dose
escalation studies (NCT00456157, NCT01133613).
Targeting bone remodelling
Recent evidence from animal models and from clinical studies
suggest that pathological remodelling of the subchondral bone in
OA29e33 may actually precede and mediate cartilage degenera-
tion33e39. It is therefore questionable whether any therapeutic
targeting a single target involved in cartilage matrix homeostasis is
likely to elicit effective disease-modifying efﬁcacy in human OA
disease. Thus it is critical to also consider the opportunities for
identifying and developing therapeutics that mediate bone
remodelling, as well as attempting to better understand the cross-
talk between OA cartilage and bone tissues since this may present
an attractive therapeutic approach.
OA subchondral bone is characterised as “sclerotic”, being
hypomineralised with a thickened and irregular trabecular struc-
ture suggestive of abnormal bone remodelling and altered
osteoblast-osteoclast coupling. The phenotype is distinct from an
osteoporotic phenotype since there is often no reduction in bone
volume. However, despite this difference, many clinical studies in
patients with OA have been conducted using anti-resorptive
bisphosphonates, which are ﬁrst-line treatments for osteoporosis.
Although in some studies bisphosphonates have shown improve-
ments in pain scores40, they have not as yet shown any disease-
modifying efﬁcacy in patients with OA41. Preclinical efﬁcacy with
calcitonin42, which binds to the calcitonin receptor on osteoclasts
and inhibits bone resorption led to its investigation in phase II
(NCT00376311) and III clinical trials (NCT00704847). However,
recent indication of an elevated risk of prostatic cancer has led to
these clinical studies being terminated.
More promising is the recently disclosed clinical trial data on
strontium ranelate, which is currently indicated for the treatment
of osteoporosis in post-menopausal women. Previous in vitro
studies have shown that strontium inhibits bone resorption and
stimulates bone formation43,44. In vivo studies conducted in a
canine model have also shown that strontium ranelate reduces OA
progression45. Most signiﬁcantly, a recent phase III study
(ISRCTN41323372) conducted in a population (n ¼ 1371) with knee
OA (Kellgren and Lawrence grade 2e3, and joint space width 2.5e
5 mm) reported that strontium administration (1 g/day) was
associated with smaller degradations in joint space width than
placebo and that fewer patients in the treated group exhibited
radiological progression. Furthermore, reductions in indicators of
knee pain and improvements in physical function were noted
following the administration of 2 g/day strontium4.
An alternative strategy is to target osteoclast proteolytic activity
by developing small molecule inhibitors to Cathepsin K (CatK). CatKis a lysosomal protease which is highly expressed in actively
resorbing osteoclasts where it mediates the degradation of matrix
proteins46 and its expression has been conﬁrmed in the synovium
of OA patients47. Targeted deletion of CatK leads to an increased
bone mass phenotype48, suggesting a role in bone remodelling and
homeostasis. The pharmacologic inhibition of CatK usingmolecules
such as L-006235 and Odanacatib, has been shown to reduce
osteoclastic bone resorption both in vitro49 and in vivo50 whilst
allowing bone formation to continue51. Furthermore, CatK inhibi-
tion has been shown to protect subchondral bone integrity, reduce
the incidence osteophytosis46, reduce cartilage degeneration and
improve joint pain in various preclinical animal models of
OA46,52,53. Despite the availability of candidate pharmacologic
agents and encouraging preclinical ﬁndings, to date no studies have
assessed the efﬁcacy of CatK inhibition in modulating the course of
human OA. However, several clinical trials are underway to inves-
tigate the utility of CatK inhibitors in other medical conditions, such
as osteoporosis and cancer.
A potential new avenue for targeting bone remodelling in OA
could be to target the bone vasculature. Importantly, knee and hip
OA are both associated with vascular-related co-morbidities54e56,
and there is now growing evidence that vascular dysfunction may
also play a role in mediating subchondral bone remodelling in OA.
The subchondral bone in both hip and knee OA exhibits evidence of
vascular dysfunction, with vascular occlusion and reduced venous
outﬂow57,58, which may result in local hypoxia59. Furthermore,
bone ischemia has been linked to bone marrow lesions (BMLs),
which are one of the morphological hallmarks of OA bone and are
strong predictors of progressive cartilage degeneration and pain.
Recent analysis of BMLs from patients with knee OA showed
that these lesions consisted of highly under-mineralised sclerotic
bone with histopathology features of secondary modelling of ves-
sels, evidence of ﬁbrosis and multiple thrombus inclusions,
consistent with a localised oxygen deﬁcit60. We recently found that
osteoblasts isolated from subchondral bone exhibited a hypomin-
eralised OA bone phenotype when cultured under hypoxic condi-
tions (unpublished). Therapeutics that are capable of targeting local
hypoxia (i.e., angiogenic modulators) in the OA bone microenvi-
ronment could therefore be a potential strategy to prevent
pathological bone remodelling opening the opportunity for the re-
proﬁling of candidate drugs from the cardiovascular therapeutic
area.
Targeting inﬂammation
Inﬂammation is now recognized as an important pathological
driver in OA, even where there is the involvement of mechanical
factors in OA development such as in meniscal injury or anterior
cruciate ligament tear. MRI, immunohistochemical studies and ul-
trasonography have all demonstrated synovitis in early OA with
increased cellular inﬁltrate of macrophages and T cells61. Further-
more, elevated levels of several pro-inﬂammatory cytokines
including IL-1b, TNFa, IL-6, IL-8 have been detected in the synovial
ﬂuid and serum of patients with OA compared to healthy in-
dividuals. Importantly, the effect on ex-vivo cartilage and bone
tissue of stimulation with cytokines such as TNFa and IL-1b mimic
the structural changes observed within the OA joint62 strongly
suggesting that an anti-inﬂammatory therapeutic could positively
affect cartilage integrity and bone remodelling.
Despite their success in treating rheumatoid arthritis (RA),
monoclonal antibodies targeting TNFa have disappointed in clinical
studies in OA patients, showing only limited effectiveness in painful
OA but no disease modiﬁcation (NCT00597623). IL-1b antagonists
have also been trialled, but pralnacasan was halted in phase II due
to the emergence of liver toxicity data (Wieland HA 2005), whilst
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endpoints (NCT00110942)63. Given the multitude of cytokines re-
ported to be elevated in OA joints it would appear likely that tar-
geting of multiple cytokines would be required to achieve efﬁcacy.
However, targeting of multiple cytokines would also be expected to
increase the risk of infection and thus such an approach is currently
deemed unsuitable for chronic administration.
Another approach to targeting inﬂammation in OA is to target
the arachidonic acid pathway. As previously noted, NSAIDs failed in
the clinical due to adverse side effects. Cycoloxygenase-1 (COX-1)
inhibitors such as Aspirin resulted in gastrointestinal adverse
events, whilst COX-2 inhibitors were associated with severe car-
diovascular side effects. The cardiovascular side effects of COX in-
hibition have since been attributed to the effect of COX-2 inhibition
on the balance of prostacyclin and thromboxane A (TxA) with an
increase in the relative levels of TxA favouring prothrombotic
events. An alternative strategy is therefore to target both arms of
the arachidonic acid pathway so as not to disrupt the prostacyclin/
thromboxane balance and avoid the cardiovascular side effects.
Licofelone is a COX and lipoxygenase (LOX) inhibitor with no re-
ported gastrointestinal or cardiovascular side effects at efﬁcacious
concentrations64. Preclinical studies have shown that licofelone
administration prevents the morphological and biochemical
changes characteristic of early experimental OA65, and suggest that
this is mediated by a reduction in MMP-13 and Cathepsin K syn-
thesis. Furthermore, licofelone has been shown to signiﬁcantly
reduce cartilage volume loss (vs patients taking a standard NSAID
alone) in a recent human clinical trial of knee OA patients66.
Nitric oxide (NO) plays an important role in inﬂammatory pro-
cesses and is considered to be one of the key mediators of cartilage
destruction in OA67. NO is induced by IL-1, a cardinal OA cytokine,
via the inducible NO synthase pathway (iNOS)68 and is elevated in
both experimental69 and human OA70, In this regard, NO mediates
many of the pathogenic effects of IL-1 through the activation of
MMPs, the inhibition of proteoglycan and collagen synthesis and
the enhancement of inﬂammation71. The iNOS pathway has been
considered an attractive target for disease-modifying drugs and is
currently the subject of several preclinical studies. The pharmaco-
logic inhibition of iNOS has been shown to reduce progression and
pain in the murine monosodium iodoacetate (MIA)-induced model
of osteoarthritic pain72, and reduce disease progression in a canine
model of experimental OA73,74. However, a recent clinical trial
investigating the safety and efﬁcacy of SD-6010, a novel iNOS in-
hibitor on slowing OA progression in a cohort of overweight and
obese patients with knee OA (clinical trial NCT00565812) has
shown that whilst well tolerated, iNOS inhibition failed to slow the
rate of JSN vs a placebo treatment over a course of 96 weeks75.
Noteworthy is that this study population consisted predominantly
of obese female OA patients (>75%). Given that OA is a heteroge-
neous condition, it is unclear whether the lack of beneﬁcial effect
noted was speciﬁc to the patient subgroup studied.
In addition to the study by le Graverand et al. (2013), More et al.
also investigated iNOS inhibition as a potential route for therapy in
OA patients72. S-methylisothiourea (SMT) was found to be partic-
ularly effective in reducing NO. Using aMIA-inducedmodel of OA in
rats, 30 mg/kg SMT was found to reduce NO production in synovial
ﬂuid. This was complemented by histopathological evidence sug-
gesting a reduction in disease progression through measures of
intact cartilage. Translatability into human subjects is a vital next
step for this work but early evidence is encouraging. Furthermore,
in light of the availability of well tolerated inhibitors and positive
preclinical data, it is plausible that iNOS inhibition may prove a
useful addition to combination therapies designed to target mul-
tiple hallmarks of the disease. In this regard, further studies of iNOS
inhibition in other OA patient cohorts could be fruitful.Inhibitors of p38 MAPK are efﬁcacious in reducing MMP pro-
duction in bovine cartilage explants76. Furthermore, p38 MAPK
inhibition has been shown to reduce cartilage degradation in mu-
rine preclinical models of OA77. Despite these positive ﬁndings, p38
inhibitors cannot be given systemically since p38 MAPK has both
pro-inﬂammatory and anti-inﬂammatory functions dependent on
the cell type. An alternative strategy is therefore to develop ther-
apeutics that target molecules downstream in the p38 MAPK
pathway thus providing a more selective targeting approach. In
preclinical ex-vivo OA models we have previously demonstrated
that inhibition of MAPKAPK2 (MK2) is as effective as p38 inhibition
at reducing the cytokine-mediated release of MMPs and PGE2 in
human OA cartilage tissue62. Therefore small molecule inhibitors
developed against MK2 or other downstream MAPKAP kinases
might enable an oral anti-inﬂammatory approach in OA.
Targeting dysfunctional skeletal muscle
Patients with knee OA exhibiting signiﬁcant muscle weak-
ness78e80 is one of the most frequent and earliest reported symp-
toms of OA. Furthermore, muscle weakness is reported in patients
with either painful or non-painful OA, suggesting that muscle
weakness may precede the onset of disease and be directly
involved in its pathogenesis81,82. Histochemical studies have shown
speciﬁc atrophy of type II muscle ﬁbres in the quadriceps muscles
of patients with knee OA83 and in the hip muscles of patients with
hip OA84.
Although it is unclear whether a strong quadriceps muscle can
be a protective factor in the initiation of knee OA85,86, there is
extensive clinical evidence to suggest that strengthening lower
limbs through exercise may improve OA symptoms87e92 in patients
with established OA. Furthermore, the beneﬁts of exercise and diet-
induced weight loss have been investigated in overweight and
obese OA patients with beneﬁcial effects on various disease pa-
rameters93. However, improving skeletal muscle strength and
functional performance through intensive exercise regimes is often
inappropriate for the many OA patients who are elderly, over-
weight, co-morbid and may be frail. Therefore, the development of
pharmacological agents, that, either alone or in combination with
adjuvant exercise programs, are capable of mimicking intensive
exercise regimes by improving muscle function in knee OA patients
could provide a plausible route through which to modify the dis-
ease course of OA during both initiation and late-stage progression.
Several pharmacologic agents have been shown to increase
skeletal muscle mass, including androgens such as Testosterone94.
Therefore, selective androgen receptor modulators (SARMs) that
are selectively anabolic hold promise as anabolic therapeutics. In
addition to increasing muscle mass, various agents have been
shown to modulate skeletal muscle ﬁbre type composition. For
example, b2-adrenergic agonists such as clenbuterol increase
muscle mass, decrease adiposity95 and induce a slow to fast ﬁbre
type transitions96, whilst thyroid hormone administration induces
slow to fast ﬁbre type transitions with associated increases in
contractile activity97. Although several pharmacological agents
elicit well described effects on skeletal muscle, their utility in OA
disease is hampered at present by our lack of understanding of the
precise spectrum of changes taking place within the muscle ﬁbres
in response to OA development and the lack of an appropriate
musculoskeletal animal model of OA for preclinical studies. Indeed,
a previous study investigating the use of a muscle modulating
agent prior to the induction of experimental surgically induced OA
failed to modulate the disease course in the rodent. However, the
authors acknowledged that the rapid rate of OA development in the
preclinical model utilised may have masked any potential
beneﬁts98.
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changes taking place in OA skeletal muscle in order to identify the
most suitable muscle targets for modulation (muscle mass per se,
ﬁbre type, contractility, metabolic potential or a combination) and
develop better translational preclinical models.
Targeting adipose tissue
Recent data reveals that many knee and hip joint replacements
are attributable to patients being overweight or obese99. Specif-
ically, central adiposity is a risk factor for hip and knee OA, sug-
gesting the importance of body composition and fat distribution.
Crucially, obesity is associated with OA in both weight-bearing and
non-weight-bearing joints such as the hands100,101 suggesting that
it is not simply due to increased load on the joint.
The adipose-secreted cytokines (adipokines), which are known
mediators of metabolic homeostasis102e105, provide a mechanistic
link between metabolism and joint remodelling and erosion. The
adipokines leptin, adiponectin (APN) and resistin have all been
detected within the synovial ﬂuid of OA patients106,107 and elevated
serum levels of adipokines have been found in knee OA patients
associated with synovial inﬂammation108. Furthermore, data from
in vitro studies suggests that adipokines can mediate pathological
cartilage and bone remodelling. For example, it has been shown
that leptin can potentiate the action of pro-inﬂammatory cytokines
in human primary chondrocytes109 and stimulate osteoblast ac-
tivity and proliferation110, whilst APN has been shown to modulate
the expression of both pro-inﬂammatory cytokines and cartilage
proteases including MMP-3, MMP-9, MMP-13 and TIMP-1111e113.
Studies have shown that serum leptin levels correlate positively
to bone mineral density114e116 and we have shown in females with
knee OA that serum leptin and its soluble receptor (Ob-R) are
associated with biomarkers of bone and cartilage remodelling as
well as cartilage volume loss over a 2 year period117. Data on APN
supports a protective function in OA111 since an inverse correlation
between serum and synovial ﬂuid levels of APN and disease
severity has previously been reported in patients with knee OA118,
and it has been shown that patients with high APN levels had a
decreased risk for hand OA progression118,119.
Antagonism of the leptin axis may provide a novel therapeutic
pathway which has as yet been largely unexplored. In 2006120,
identiﬁed a monoclonal leptin receptor antagonist antibody, 9F8,
which was shown to reduce leptin-induced TNFa production from
human monocytes as well as activation and proliferation of T cells
following CD3 stimulation120. However, there is a lack of published
material exploring the potential beneﬁts of 9F8 as a therapeutic,
although many recent meeting reports do exist. However, the
identiﬁcation of 9F8 monoclonal antibody (mAb) and its in-
teractions with the leptin receptor have helped to enable a greater
understanding of the structural conformation of the leptin receptor
thus opening up further possibilities for identifying novel leptin
receptor inhibitors121.
New therapeutic applications for old drugs, termed “drug re-
proﬁling”, are becoming increasingly more common. The thera-
peutic antibody, Inﬂiximab, is an anti-TNFa therapy used predom-
inantly in rheumatoid arthritis patients122. In 2007, it was
discovered that inﬂiximab is also able to attenuate resistin in in-
ﬂammatory bowel disease (IBD) patients123. Although leptin and
APN levels remained unchanged in their patient cohort, the
reduction of resistin and subsequent amelioration of IBD symp-
toms, suggest that resistin could have a central role to play in
pathological inﬂammation. Indeed, Guler-Yuksel et al. found cir-
cumstantial evidence in RA patients with secondary hand OA who
were receiving inﬂiximab treatment that the symptoms of their
hand OA were reduced124. More work is required, however, todetermine the mechanism by which this secondary OA in RA pa-
tients is being reduced by Inﬂiximab.
APN is considered in many disease states to be a “good” adi-
pokine, being negatively associated with metabolic syndrome and
also anti-inﬂammatory action. For example, APN has been shown to
downregulate TNFa and IL-1b and to upregulate IL-10 and IL-
1RA111e113. Therefore, unlike leptin and resistin, blocking of APN
may not be beneﬁcial in combating inﬂammatory disease. Instead
topical applications of recombinant APN may be beneﬁcial in
attenuating the inﬂammatory environment, since it was recently
shown that topical applications of APN in dry eye disease in mice
reduced the inﬂammatory component of the disease125. However,
at present, no clinical trials are in progress to assess the potential
beneﬁts of APN therapy in OA disease.
Therapeutic targeting of leptin and/or APN in OA patients,
particularly those patients who are overweight or obese, could have
great potential in ameliorating disease progression and severity
through modulating the inﬂammatory environment created by
pathological adiposity. Preclinical work in this area has shown
promising results as discussed above, but further investigation into
the molecular signalling pathways mediated by adipokines in OA
diseased joint tissue and how this differs across different patient
cohorts is required. Indeed, Inﬂiximab is now being used clinically
to treat OA patients (and RA patients with secondary OA), but
therapeutic modulation of adipokines or indeed therapeutic mod-
ulation of targets within adipokine-mediated signalling pathways
are still someway away from being realised for the treatment of OA.
However, it is envisaged that the development of such agents, could
complement adjuvant weight-loss programs in OA patient cohorts
who are overweight or obese.
Potential for the development of personalised
pharmacological medicines in OA
Current OA patient stratiﬁcation is limited and predominantly
based on clinical factors such as the mechanism of disease onset
(primary or secondary OA), the involved joint, the degree of
inﬂammation, the rate of disease progression and the disease stage
(early or late OA). This clinical stratiﬁcation, combined with a
limited choice of available therapeutics, does very little to assist the
clinician in selecting the best treatment option. For the manage-
ment of patients with knee or hip OA, the OARSI recommenda-
tions126 include a combination of pharmacological and non-
pharmacological treatments. For example, patients are encour-
aged to undertake muscle strengthening/range of motion exercises,
whilst those who are overweight are encouraged to lose weight.
NSAIDs (either alone or in combination with a gastroprotective
agent for those with GI risk) are recommended for patients with
symptomatic painful OA. For those patients with moderate-severe
pain, intra-articular injections of corticosteroids are recom-
mended, particularly for those who have not responded to NSAIDs
or whose joints exhibit synovial inﬂammation.
In considering the development of a personalised DMOADs, it is
critical to recognise that OA is a highly heterogeneous condition
with potentially varying root causes across different patient
groups127, and that this heterogeneity should guide the selection of
patients and their disease stage for a particular disease-modifying
therapeutic (Table II). For example, the degree of synovitis observed
in the joints of patients with OA is highly variable, suggesting that
some, but not all patients would beneﬁt from an anti-inﬂammatory
therapeutic. Similarly, it is also recognised that some patients’ OA is
characterised as exhibiting a greater involvement of bone remod-
elling than others. Therefore patients who exhibit this “bony” OA
phenotype may bemore suitable to being treatedwith therapeutics
that directly target bone remodelling. In addition, the metabolic
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D.P. Tonge et al. / Osteoarthritis and Cartilage 22 (2014) 609e621616risk of OA may depend on the particular patient cohort. Central
adiposity (waist : hip ratio) has previously been shown to be more
strongly associated with OA in women than in men119, and we
recently found that females but not males with knee OA had
signiﬁcantly higher BMI than controls and exhibited a higher pro-
portion of generalised OA (nodal hand OA), indicative of a more
systemic condition. By contrast, in the males there was no differ-
ence in BMI between OA and controls, and no difference in the
incidence of generalised OA. However, there was a greater associ-
ation of occupational risk inmales with knee OA compared tomales
without knee OA. These data, suggest that there are different route
causes of OA, each likely requiring a different therapeutic approach.
It is also likely to be necessary to stratify OA patients not solely
on clinical measures but also biochemical, genetic and epigenetic
proﬁles. By far the best example of this is the ﬁeld of oncology
which has seen the recent approval of several therapeutics with
companion biomarker assays, which prospectively help to predict
likely response or adverse effects128. This shift towards personal-
ised medicine has been further exempliﬁed by the release of the US
Food and Drug Administration (FDA) “Table of Pharmacogenomic
Biomarkers in Drug Labels” which serves as a repository of thera-
peutic agents that have associated pharmacogenomic
requirements.
Stratiﬁcation biomarkers are categorised by their molecule class
and include genetic and expression biomarkers of nucleic acid
origin, those derived from protein, and those representing changes
in metabolite concentration129. Currently available genomic infor-
mation in patients with OA has not enabled the stratiﬁcation of
patients into subsets. However, the recent advent of next genera-
tion sequencing technologies is now rapidly accelerating the ﬁeld
of nucleic acid based biomarker discovery signiﬁcantly. Although
several competing sequencing technologies are currently available
which tend to vary only in their acquisition methods and depth of
coverage, they all offer the ability to sequence large quantities of
nucleic material rapidly and cost effectively. For example, such
technologies are suitable for the global detection of structural
(single nucleotide polymorphisms, translocations) andmethylation
changes in DNA, and the detection of expression changes in various
RNA molecule classes (mRNA, microRNA, piRNA, lincRNA).
This in depth analysis of both genomic and transcriptomic data
will provide new insights into OA patient molecular phenotype and
identify new disease subsets which should be informative in
identifying and developing personalised DMOAD therapeutics.
Furthermore, a paradigm shift towards “personalised medicine”,
where OA patients are stratiﬁed based upon molecular biomarkers
integrated with clinical pathological assessments, has the potential
to also reduce candidate drug attrition during clinical development
due to potentially efﬁcacious drugs being masked when tested on
heterogeneous population studies. This approach should therefore
accelerate the development of new personalised DMOADs for
speciﬁc OA populations.
Summary and conclusions
The recognition that OA is not simply a wear and tear disease of
the cartilage but is a multi-faceted disease involving thewhole joint
offers new opportunities to identify and develop novel disease-
modifying therapeutics and also to consider the re-proﬁling of
candidate drugs from different therapeutic areas. However, this
complexity also means it is likely that a single therapeutic agent
targeting a single target within a single tissue type may not be
sufﬁcient to achieve effective disease modiﬁcation. As in the
oncology therapeutic area we will likely need to consider combi-
nations of drugs targeting different hallmarks of OA biology.
Furthermore, given the heterogeneity of OA it is hoped that the
D.P. Tonge et al. / Osteoarthritis and Cartilage 22 (2014) 609e621 617recent emergence of improved next generation sequencing tech-
nologies will provide novel molecular phenotyping of OA patients,
which when combined with MRI and pathological assessment will
enable improved patient stratiﬁcation, thus leading to the design
and development of personalised OA therapeutics.
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